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Introduction
Specialty pharmaceuticals (hereinafter “specialty drugs”), also known as biologics,1
are an increasingly prevalent and important consideration for health insurers. By the
end of 2009, over six hundred specialty drugs were known to be in development.2
Demonstrating this development trend, the FDA approved twice as many specialty drugs

*

Chad Brooker received his J.D. from the University of Maryland School of Law in 2013. He
is currently the Chief Policy and Legal Analyst for the Connecticut Health Insurance Exchange
(d.b.a Access Health CT) and he is a former Exchange Policy expert at the Center for Consumer
Information and Insurance Oversight at the Centers for Medicare and Medicaid Services. He was
also previously the lead advisor on Specialty Pharmaceutical and FDA Trend for America’s Health
Insurance Plans (AHIP) and an Exchange Policy expert at the Center for Consumer Information and
Insurance Oversight at the Centers for Medicare and Medicaid Services.
1 See FDA 101 Regulating Biologic Products, Food and Drug Admin. (2008), http://www.fda.gov/
ForConsumers/ConsumerUpdates/ucm048341.htm (last visited Dec. 4, 2013). A “biologic drug” is
one that is made from a living organism. Id. “Biotechnology” refers to the application of biological
techniques to research and develop new products such as proteins, hormones, vaccines, monoclonal
antibodies, and gene therapy. Id.
2

Brian Schilling, Purchasing High Performance Specialty Drug Costs Poised to Skyrocket but
Many Employers Have Yet to Take Note, The Commonwealth Fund (Apr. 11, 2012), http://www.
commonwealthfund.org/Newsletters/Purchasing-High-Performance/2012/April-11-2012/FeaturedArticles/Specialty-Drug-Costs-Poised-to-Skyrocket.aspx.
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(fourteen) in 2010 as it did traditional pharmaceuticals.3 That number increased in 2011
when the FDA approved eighteen new specialty drugs.4 Furthermore, manufacturers
are increasingly investing more research and development funds in specialty drugs due
to the robust profit margins on specialty drugs.5 Since specialty drugs typically address
chronic illnesses, patients may use these drugs for a long period of time, providing
manufactures with a continuous supply of returning customers. Consequently, specialty
drugs have “been described as ‘jackpot’ drugs for manufacturers.”6
The high cost of specialty pharmaceuticals is the result of the culmination of a number
of factors. First, the development costs of producing specialty drugs are high because
scientists must rely on molecular and cellular technologies, which are often derived
from living organisms or other biological mediums rather than the chemical processes
used to make traditional pharmaceuticals.7 However, this unique development process
is also why specialty drugs typically yield significant therapeutic results with fewer
side effects.8 Furthermore, specialty drugs often require complex handling, such
as refrigeration and attention to their limited shelf life, and many require complex
administration, such as intravenous delivery, which makes them even more expensive.9
Finally, few specialty drugs have therapeutic or generic equivalents, due to existing
patents and the fact that generics are difficult to manufacture given the complexity
of their replication and production.10 This creates very limited or non-existent market
competition, allowing pharmaceutical companies to charge exceedingly high rates for
specialty drugs while continuing to raise prices year after year.11
The trend towards increased reliance on specialty pharmaceuticals would not raise such
an important concern if specialty drugs did not represent the most expensive segment
of pharmaceuticals not only for insurers, but also for consumers through cost-sharing
measures. In 2000, only one specialty drug was on the list of the top ten selling drugs.12
In 2010, three of the top ten selling drugs were specialty pharmaceutical products.13
Individuals within the pharmaceutical industry predict that by 2016, seven of the top

3 Leah Perry, 2012 Drug Pipeline: Researchers, Industry Experts Remain Optimistic, Drug Topics
(Jan. 15, 2012), http://drugtopics.modernmedicine.com/drugtopics/Modern+Medicine+Now/2012Drug-Pipeline-Researchers-industry-experts-re/ArticleStandard/Article/detail/756729.
4

Id.

5

Shilling, supra note 2.

6

Id.

7

See supra note 1.

8

Id.; see also Perry, supra note 3.

9

Adam J. Fein, 7 Reasons Why Specialty Drug Dispensing Will Boom, Specialty Pharmacy Times
(May 29, 2012), http://www.specialtypharmacytimes.com/publications/specialty-pharmacytimes/2012/June-2012/7-Reasons-Why-Specialty-Drug-Dispensing-Will-Boom.

10

See supra note 1; see also Perry, supra note 3.

11

Specialty Drug Benefit Report, Pharmacy Benefit Management Institute (2013), available at
http://www.specialtydrugbenefitreport.com (last accessed Dec. 4, 2013).

12

2000 Drug Trend Report, Express Scripts (2000), available at http://www.drugtrendreport.com/
docs/DTR-2000.pdf; see also Schilling, supra note 2.

13

Fein, supra note 9.
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ten selling drugs will be classified as specialty pharmaceutical products.14 According to
the Pharmacy Benefit Management Institute’s 2012 report, insurance plans report that
the average monthly cost of a specialty drug is at least $2,000.15 Tretinoin, a specialty
drug that can help manage some complications of leukemia, costs $6,800 a month.16
The most expensive cancer specialty treatments can cost upwards of $750,000 per year
for a single patient.17 A 2011 AARP study reported that the average annual cost for
a patient who was taking just one specialty drug was $34,550.18 Specialty drugs do
not typically face competition from generics or other drugs, so manufacturers have not
hesitated to raise the prices of such drugs annually.19 As the prevalence and costs of
these drug regimens increases (with a seventeen percent increase in average cost in 2011
and a twenty percent average increase in 2012), insurance plans have sought to control
their spending on specialty drugs through a number of formulary policies, as well as
increased cost-sharing.20
Insurers have reacted to the large and increasing costs of pharmaceuticals, attributed
in part to the high costs of specialty drugs, by shifting some of the burden of these
costs back onto the insurance policy beneficiaries.21 The most common method of
achieving this is through the creation of specialty tiers. Tiering generally refers to a
health plan placing a drug on a formulary or preferred drug list, which classifies drugs
as generic (tier one), preferred brand (tier two), or non-preferred brand (tier three)
pharmaceuticals.22 The idea of paying differing amounts of money for different types
of prescription drugs is not a new concept. Employers and insurers have long used tiers
to set the amount that patients pay for generic drugs, brand-name products, and nonpreferred brand-name drugs. A large majority of beneficiaries in employer-sponsored
14

Id.

15

Specialty Drug Benefit Report, supra note 11; see also The Growing Cost of Specialty
Pharmacy—Is it Sustainable?, Am. J. of Managed Care, http://www.ajmc.com/payerperspectives/0213/The-Growing-Cost-of-Specialty-PharmacyIs-it-Sustainable (last visited Dec. 21,
2013).
16

See Specialty Drug Benefit Report, supra note 11.

17

Schilling, supra note 2; see also 2012 Drug Trend Report, Express Scripts (2013), http://www.
drugtrendreport.com/docs/DTR-FullPDF-1029.pdf.

18

Susan Dentzer, Slowing the Impact: The Role of Specialty Pharmacy in Managing Progressive
and Chronic Diseases, United Health Grp. (April 2011), http://www.unitedhealthgroup.com/news/
rel2011/Specialty-Pharmacy-WP-Diseases.pdf.
19

Schilling, supra note 2.

20

See Specialty Drug Benefit Report, supra note 11; see also 2012 Drug Trend Report, supra note
17.
21 Mari Edlin, Specialty Tier Falls Out of Favor Because of Access Issues, Formulary J. (Jan 1,
2012), http://formularyjournal.modernmedicine.com/news/specialty-tier-falls-out-favor-becauseaccess-issues (“In Medicare, 100% of Part D enrollees in Medicare Advantage-Prescription Drug
Plans (MA-PDPs) and 94% in Medicare stand-alone Prescription Drug Plans (PDPs) are in plans
with a specialty tier. The median coinsurance for specialty drugs under PDPs—those costing at least
$600 per month—increased from 25% in 2006 to 30%, while MA-PDPs showed a change of 25%
to 33%. About half of PDPs charge a 33% coinsurance, while more than three-fourths of MA-PDPs
do.”).
22

National Patient Advocate Foundation. White Paper: Specialty Tiers (May 2013), http://www.
npaf.org/files/5%207%2013%20Specialty%20Tiers%20White%20Paper%20Final_0.pdf.
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health care plans have a tiered cost-sharing structure for prescription drug coverage.23
Given that cost-sharing generally increases with higher tiers, these types of insurance
policies have helped increase the use of generic drugs, which are generally cheapest and
on which insurers receive the largest discounts.24
Under a traditional three-tier prescription drug formulary, a beneficiary is given a choice
between more and less expensive equivalent medications for the same disease or health
condition. Thus, a beneficiary who is prescribed a tier three drug can decide that he or
she does not want to pay the higher copayment and find a chemically equivalent drug
at a lower cost on tiers one or two. As such, three-tier plans are said to achieve the
following:
(1) they provide a tool to discourage beneficiaries from making choices that
lead to utilization of higher-cost drugs (i.e., discourage moral hazards); (2) they
reduce demand for brand-name drugs that was exacerbated by drug company
advertising; (3) they move away from undifferentiated drug copayments and
help control costs; (4) they offer beneficiaries a choice of medications for a
particular disease or condition that vary in cost but not in effectiveness; and
(5) because they lower a health insurance company’s overall cost to provide
insurance, they allow the health insurance company to increase the number of
persons who can access insurance benefits and/or lower insurance costs for the
individuals already in the insurance pool.25
However, unlike the first three tiers, specialty drugs appearing on specialty drug tiers (i.e.,
tiers four and higher) often do not have generic or lower-cost brand-name equivalents.26
Specialty tiers—tiers four and beyond—began to expand in 2006 once the strategy was
adopted by Medicare Part D.27 With Medicare leading the movement, an increasing
number of private plans have created a fourth (or higher) tier of drug cost-sharing that
is used for specialty or lifestyle drugs.28 Today, about eighty-five percent of Medicare
drug plans include such tiers.29 As the prevalence of specialty pharmaceutical regimens
23

Gary Claxto et al., Employer Health Benefits: 2012 Summary of Findings, The Kaiser
Family Foundation & Health Research and Education Fund. 4 (Sept. 11, 2012), http://
kaiserfamilyfoundation.files.wordpress.com/2013/03/8345-employer-health-benefits-annual-surveyfull-report-0912.pdf (“Over three-quarters (78%) of covered workers are in plans with three or more
tiers of cost-sharing, a figure that has increased tremendously in the past decade.”).
24

Julie Appleby, Specialty Drugs Offer Hope, But Can Carry Big Price Tags, USA Today, Aug. 8,
2011, http://usatoday30.usatoday.com/money/industries/health/drugs/story/2011/08/Specialty-drugsoffer-hope-but-can-carry-big-price-tags/50090368/1.

25

Joseph J. Hylak-Reinholtz & Jay R. Naftzger, Is It Time to Shed A “Tier” for Four-Tier
Prescription Drug Formularies? Specialty Drug Tiers May Violate HIPAA’s Anti-Discrimination
Provisions and Statutory Goals, 32 N. Ill. U. L. Rev., 33, 42 (2011).
26
of

Bill Walsh, The Tier 4 Phenomenon: Shifting the High Cost of Drugs to Consumers, Amer. Assn.
Retired Persons (Mar. 9, 2009), http://assets.aarp.org/rgcenter/health/tierfour.pdf.

27

Julie Appleby, Workers Squeezed as Employers Pass Along High Costs of Specialty Drugs, Kaiser
Health News (Aug. 22, 2011), http://www.kaiserhealthnews.org/stories/2011/august/22/workerssqueezed-as-employers-pass-along-high-costs-of-specialty-drugs.aspx.

28

Id.

29

Id.

28
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has grown, the popularity of specialty plans has grown accordingly.30 Many payors
see specialty tiers as an essential element that allows a higher percentage of the drug
spending burden to be carried by those who are utilizing higher cost products, allowing
beneficiaries who are not using such drugs to maintain lower premiums and costsharing.31 Specialty tiers can either use a coinsurance or a copay cost-sharing scheme.
Under a coinsurance scheme, the beneficiary will pay a certain percentage of the costs of
the drug and the insurance company will pick up the remainder of the cost. Commonly,
coinsurance rates for the specialty tiers range from twenty-eight to fifty percent.32 As
such, coinsurance is a burden for beneficiaries in that the costs of specialty drugs are
very expensive and a requirement to pay a sizable percentage of that cost can amount
to several hundred or thousands of dollars per month in cost-sharing. Among plans
with four or more tiers, in 2012, fifty-five percent of those plans used only a copay—
often about $100 per prescription per month—and thirty-six percent of plans used only
coinsurance, percentage based cost-sharing—the average percentage was thirty-two
percent.33
The insurance industry defends the creation of four-tiered plans, but the use of such
plans has been met with severe criticism. Patient advocates argue that four-tier plans are
unjust because insurance is supposed to spread the risk in an equitable fashion among
all insured beneficiaries.34 However, specialty tiers target those with chronic illness
who may have very limited therapeutic options, “forcing many to choose between basic
necessities and their medications.”35 On the other hand, insurance industry advocates
argue that the use of specialty drugs has risen dramatically and having a tiered system
helps to control the costs of premiums for all beneficiaries.36 Karen Ignagni, the
President of America’s Health Insurance Plans, noted that “[p]rivate insurers began
offering [specialty drug] plans in response to employers who were looking for ways to
keep costs down.”37 She further noted, “[w]hen people who need [specialty] drugs pay
more for them, other subscribers in the plan pay less for their coverage.”38
The prevalence of fourth tier plans varies dramatically across health care markets. Fourtier designs are much less prevalent in markets characterized by historically high levels
of unionized labor where the corporate benefits structures have been slow to disfavor
30

Gary Claxto et al., supra note 23, at 149 (“Fourteen percent of covered workers are in a plan that
has four or more tiers of cost-sharing for prescription drugs—up from 3% in 2005. For covered
workers in plans with three or more cost-sharing tiers, 55% face a copayment for fourth-tier drugs
and 36% face coinsurance. The average copayment for a fourth-tier drug is $79 and the average
coinsurance is 32%.”).
31

Id.

32

Id.

33

Id.

34

See National Patient Advocate Foundation, supra note 22.

35

Kris McFalls, An Update on Specialty Tier Legislation, FFF Enters. (Oct. 7, 2011), http://www.
fffenterprises.com/News/Article_2011-10-07.aspx.

36 Gina Kolata, Co-Payments Soar for Drugs with High Prices, N.Y. Times, Apr. 14 2008, http://
www.nytimes.com/2008/04/14/us/14drug.html?pagewanted=all&_r=0.
37

Id.

38

Id.
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valuable fringe benefit schemes.39 Four-tier penetration also varies greatly by market
segment: “the smaller an employer, the greater the price-consciousness and likelihood
of adopting a four-tier design. Finally, differences among health plan and employer
philosophies and strategies are key in four-tier adoption.” 40 There is also a difference
among insurance companies in adoption of the four-tier design. For example, Aetna and
WellPoint have widely adopted four-tier designs.41 In contrast, Cigna, does not offer
four-tier pharmacy benefits in its fully insured product line; however, upon request from
self-insured employers, it can provide these insurance products.42 More recently, state
legislatures have played an important role in affecting the prevalence of four-tiered plans
as they seek to alleviate the cost-sharing burden on health insurance beneficiaries.43

I. The Cost-sharing Burden of Specialty Tiers
Specialty drugs have represented the fastest growing segment of health insurance
prescription drug spending for much of the last decade.44 This trend should concern
private health insurance payors because specialty pharmaceuticals are very expensive
and most are too new, complex, or expensive to produce to experience competition from
other branded drugs or generics (biosimilars).45 While specialty drugs are only used by
a small percentage of the population—potentially as low as two percent46—specialty
drugs accounted for approximately twenty-four percent of total drug expenditures in
2011 and thirty percent of the $325.7 billion in drug expenditures in 2012.47 Moreover,
39 Ha Tu & Divya Samuel, Limited Options to Manage Specialty Drug Spending, HSC Research
Brief (Apr. 2012), http://www.hschange.com/CONTENT/1286.
40

Id.

41

Id. (“[A]bout half of their small-to-mid-sized group members were covered by such designs as of
2011.”).
42

Id. (“[C]iting concerns about affordability and patient adherence . . . .”).

43

New York, California, Connecticut, Delaware, Hawaii, Maryland, Massachusetts, New Mexico,
Rhode Island, Vermont, Washington, Illinois, Indiana, Nebraska, Pennsylvania, Virginia, Louisiana,
Florida, West Virginia, Alaska, Kansas, Mississippi, Maine, and Wisconsin all have previously
introduced legislation regarding the use of specialty tiers in their state. However, only seven states
have actually passed laws relating to tiering, and only ten states have active bills. Author research.
See also Andrew Pollack, States Seek to Curb Patients Bills for Costly Drugs, N.Y. Times, A1, Apr.
13, 2012, http://www.nytimes.com/2012/04/13/health/states-seek-to-curb-exorbitant-drug-costsincurred-by-patients.html?pagewanted=all&_r=0.
44

See Specialty Drug Benefit Report, supra note 11.

45

Biosimilars are generic versions of biologics that must prove that they are “biosimilar” and
“interchangeable” with biologic reference products (the branded drugs) in order to be approved
for sale in the consumer market. While the Biologics Price Competition and Innovation Act (part
of the ACA) will help to create an abbreviated approval process for biosimilars so that they may
gain easier and quicker FDA approval as long as they meet the Agency’s standards for safety
and efficacy. Biosimilars, Food and Drug Admin. (July 10, 2012), http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/
TherapeuticBiologicApplications/Biosimilars/default.htm.
46

Ira Studin, 4 Payer Trends to Control Specialty Pharmacy Costs, Managed Care (May 2012),
http://www.managedcaremag.com/archives/1205/1205.sp_trends.html.
47

The Growing Cost of Specialty Pharmacy—Is it Sustainable?, supra note 15. In 2010, total
national health expenditures were $2.59 trillion dollars with retail prescription drugs accounting for
10% of that amount or $250 billion. Martin A.B. et al., Growth In US Health Spending Remained
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specialty drugs are anticipated to account for forty-five percent of total drug expenditures
by 2017—up from a mere eight percent in 2006.48 To put this in perspective, with
current plan utilization rates, a moderately sized plan of one million members will be
approaching one billion dollars in specialty drug spending annually.49 Of these costs,
almost fifty percent of which will be oncology related—cancer biologic costs increased
22.3 percent in 2012 alone.50 If annual trends of twenty percent growth for spending
on specialty drugs continue, that number will again double in less than four years.51
The damaging potential of this growth has been muted due to the overall downward
shift in drug costs in recent years as generic usage has increased; for example, in 2012,
traditional drug spending actually decreased while specialty drug spending increased by
18.4 percent.52 Reacting to this trend, insurance companies have developed prescription
drug formularies with four or more tiers (hereinafter “specialty tiers”), in order to control
the rising costs associated with expensive specialty drugs by sharing a greater amount of
those costs with their patients.53 While increased specialty drug cost-sharing is certainly
warranted, the strain that it places on patients can create negative health and personal
externalities.54 As such, further effort should be exerted to reduce the burden on those
patients who depend on these drugs and who often lack alternative treatment options.55
The key feature of specialty drug tiers is a drastically increased cost-sharing component,
with the consumer paying a larger amount of the cost for expensive drugs. Such costsharing can take the form of much higher copayments, where the consumers pay a
certain defined price for a drug in that category or coinsurance, where the consumer
pays a percentage of the actual cost of the drug. The practice of cost-sharing has been
widely criticized by politicians and patients who cite examples of destructive costsharing which could force a person to decide between a certain medication and other
personal or familial necessities.56 Because most specialty drugs are used to treat chronic
Slow in 2010; Health Share of Gross Domestic Product Was Unchanged from 2009, Health
Affairs (2012). In 2012, total drug expenditures had risen to $325.7 billion and specialty drug
expenditures accounted for $99 billion of that number. Katie Thomas, U.S. Drug Costs Dropped in
2012, but Rises Loom, N.Y. Times, Mar. 18, 2013, http://www.nytimes.com/2013/03/19/business/
use-of-generics-produces-an-unusual-drop-in-drug-spending.html?pagewanted=all; Understanding
Specialty Pharmacy Management and Cost Control, Pharmaceutical Strategies Group (June
2010), http://www.psgconsults.com/Understanding_Specialty_Pharmacy_Management_and_Cost_
Control_FINAL.pdf.
48

The Growing Cost of Specialty Pharmacy—Is it Sustainable?, supra note 15; see also 2012
Drug Trend Report, supra note 20; Kim, Yoona A., et al, Retrospective Evaluation of the Impact
of Copayment Increases for Specialty Medications on Adherence and Persistence in an Integrated
Health Maintenance Organization System (Nov. 5, 2011).
49 Artemetrx, Specialty Drug Trend Across the Medical and Pharmacy Benefit (2013), http://www.
artemetrx.com/docs/ARTEMETRX_Specialty_Trend_Report.pdf
50

Id.; see also The Growing Cost of Specialty Pharmacy—Is it Sustainable?, supra note 15.

51

Id. According to the Express Scripts, 2012 Drug Trend Report, specialty trend (cost rate change +
utilization rate change) rose 18.4% in 2012. 2012 Drug Trend Report, supra note 17.
52

Id.; Katie Thomas, supra note 47.

53

See Kim, Yoona A., et al, supra note 48.

54

Id.

55

Id.

56

Pollack, supra note 43.
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diseases such as cancer, rheumatoid arthritis, multiple sclerosis, and inherited disorders,
the long-term costs to both the insurers and the patients raises serious concerns.
Spurred by patients and patient advocates, lawmakers in at least twenty states from
Maine to Hawaii, have introduced legislation that would either ban specialty tiers or limit
aggregate out-of-pocket payments by consumers for expensive specialty tier drugs.57
New York State passed the first such law, in 2010, prohibiting the use of specialty
tiers across the board for beneficiaries of plans offered in the state.58 Pharmaceutical
companies—that would benefit from such legislation because high copayments
discourage patients from taking medications sold by pharmaceutical companies—have
been helping the state legislatures craft such specialty tier limiting legislation.59 Some
companies, like Pfizer, have even drafted entire bills and have provided them to state
legislatures, according to legislators and patient advocates.60 Insurance companies are
pushing back, arguing that reducing payments by users of expensive drugs would raise
premiums for everyone else.61
State legislators must carefully consider the potential that their attempted protective
measures—that ban specialty tiers or limit aggregate out-of-pocket payments by
consumers for expensive specialty tier drugs—will be limited in effect by the Employee
Retirement Income Security Act of 1974 (ERISA).62 ERISA preemption applies to
nullify state insurance laws that apply to self-insured ERISA plans.63 As an ode to the
traditional areas of state regulation, as evidenced by the McCarran Ferguson Act,64
state laws directed at the business of insurance are saved from preemption by § 514 of
ERISA,65 also known as the “insurance savings clause.” However, self-insured plans,
where the employer funds the plan and takes on the risk in the plan, are not “deemed” to
be in the business of insurance due to the “Deemer Clause,” which is also part of § 514
of ERISA.66 As such, only insured health benefit plans must comply with state insurance
57

Id.

58

See id.

59

Id.

60

Id.

61

Id.

62

Employee Retirement Income Security Act of 1974 (ERISA), Pub. L. No. 93-406, 88 Stat. 829
(codified as amended in scattered sections of 5 U.S.C., 18 U.S.C., 26 U.S.C., 29 U.S.C., and 42
U.S.C.) (1974).
63

Id. § 514.

64

McCarran-Ferguson Act, 15 U.S.C. §§ 1011-1015 (1976) (“Congress hereby declares that the
continued regulation and taxation by the several States of the business of insurance is in the public
interest, and that silence on the part of the Congress shall not be construed to impose any barrier to
the regulation or taxation of such business by the several States. [§2.] (a) The business of insurance,
and every person engaged therein, shall be subject to the laws of the several States which relate to
the regulation or taxation of such business. (b) No Act of Congress shall be construed to invalidate,
impair, or supersede any law enacted by any State for the purpose of regulating the business of
insurance, or which imposes a fee or tax upon such business, unless such Act specifically relates to
the business of insurance.”). ERISA carved out an area of federal preemption with respect to such
traditional state governance.
65

ERISA, 29 U.S.C. § 514(b)(2)(A).

66

ERISA, 29 U.S.C. § 514(b)(2)(B).
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mandates, and state laws seeking to limit specialty drug cost-sharing are similarly
limited to only insured plans.67 Considering that more than half of Americans with
employer sponsored plans have self-insured plans, such laws alone cannot totally solve
the concern of high specialty drug cost-sharing.68 However, this potential limitation
should not discourage state efforts to pass such cost-sharing legislation.
State tier limiting legislation is significantly augmented by the out-of-pocket limits on
prescription drug spending that are created by the Affordable Care Act (ACA),69 which
will, as of January 1, 2014, apply to both insured and self-insured plans having plan
years stating on or after January 1, 2014.70 Some insurers have indicated that state laws
limiting specialty cost-sharing are unnecessary because of the ACA, however, backers
of such legislation argue that the state bills would serve as an important supplement to
the federal law. While the ACA serves to alleviate some of the cost-sharing concerns for
patients as well as the discrepancies between insured and self-insured plans, the costsharing limits may remain burdensome for some families.71 The ACA reduces the burden
on those individuals who are paying the most for their pharmaceuticals, but there will
still be a role for states to further assist those who depend on specialty pharmaceuticals
from almost assuredly reaching the ACA’s maximum cost-sharing limits ($6,350 in
2014 for an individual plan or $12,700 for a family plan) which can be very financially
burdensome considering that these payments are in addition to premium costs.72
67

See e.g., American Medical Security v. Bartlett, 111 F.3d 358 (4th Cir. 1997).

68

Paul Fronstin, Self-Insured Health Plans: State Variation and Recent Trends by Firm Size,
Employee Benefit Research Inst. (Nov. 2012). In 2011, 58.5% of workers with employer-provided
health coverage were in self-insured plans. Id.
69

Patient Protection and Affordable Care Act (ACA), Pub. L. No. 111-48, § 2702, 124 Stat. 119,
318-19 (2010).
70

Id. The ACA applies to both insured and self-insured plans since the legislation made
amendments to the Public Health Service Act (PHSA) as well as the Internal Revenue Code sections
as they apply to ERISA in order to reach all non-grandfathered plans, whether insured or selfinsured. ACA § 1301; ACA § 1201 (adding § 2707(b) (applying cost-sharing limits to “group health
plans” which had been defined to encompass self-funded plans) to the PHSA.); and ACA § 1302(c).
71

See infra Section V.

72

The ACA cost-sharing limits for 2014 were pegged to the High Deductible Health Plan (HDHP)
deductible minimums for 2014 which are set year by the Internal Revenue Service (IRS). For 2015
and beyond, the cost-sharing limits will be set through a uniform percentage increase that will be
decided by the premium adjustment percentage which is set by CMS in their yearly Benefit and
Payment Parameters rulemaking. See ACA, Pub. L. No. 111-48, § 1302(c)(1), 124 Stat. 119, 47-48
(2010). It should be noted that there are diminished cost-sharing limits for those who are at or below
250% of the FPL. Limits for those individuals are set at fractions of the OOP limits set for that
given year. They are as follows: enrollees with a household modified adjusted gross income (MAGI)
between 100% and 150% of the FPL will be eligible for plans with a 2/3 reduction in the maximum
annual limitation on OOP cost-sharing; enrollees with household MAGI between 150% and 200%
of the FPL will be eligible for a different set of plans at the respective AV level required by the ACA
for such subset that also has a 2/3 reduction in the standard maximum annual limitation on OOP
cost-sharing; enrollees with household MAGI between 200% and 250% of the FPL will be eligible
for a different set of plans at the respective AV level required by the ACA for such subset that also
has a 1/2 reduction in the standard maximum annual limitation on OOP cost-sharing. The FPL for
2014 is $11,490 for an individual and requires the addition of $4,020 for each additional person.
(i.e., a couple is $15,510). See 2014 Notice of Benefit and Payment Parameters, 78 Fed. Reg. 15410
(March 11, 2013).
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States should take note, however, that while the ACA has assisted their efforts in
protecting citizens from high costs of specialty drugs, the ACA also stated that the
state may face increased costs if they seek to limit cost-sharing further than the ACA
mandates through state legislation.73 The ACA requires states that pass laws, after
December 31, 2011, that act to strengthen or add to the benefits required to be covered
as Essential Health Benefits (EHB) than what appeared in their benchmark plans, as
chosen by the state in accordance with the ACA, must defray any additional costs, to the
beneficiary or the carrier, in relation to those increased coverage requirements; this has
been deemed the “make-whole requirement.”74 While some states have argued that costsharing limitations are not an additional benefit but a constraint on plan design—which
escapes this “make-whole requirement”—the precarious position of many state budgets
could make this risk too much to bear—causing specialty drug related legislative efforts
to disappear.75 Even with this risk in mind, states have continued to legislate to create
tighter restrictions on patient cost-sharing (although with diminished success rates),
but they have placed language in the bills that would protect the state, by invalidating
the law, should they be required to defray the associated costs.76 However, a careful
reading of the rules related to such cost-sharing laws show that state specialty drug
out-of-pocket limits reduction laws should escape cost defrayment requirements set
forth in the ACA.77 As such, states should seek to further protect their residents from
excessive cost-sharing, with respect to specialty drugs, by passing legislation similar to
the legislation that has been enacted in New York, or legislation which sets diminished
caps on specialty cost-sharing.

II. States React to Specialty Tiers
To protect consumers and address the increasingly expensive cost of specialty
pharmaceuticals, legislators from states across the country have introduced or passed
73

See ACA, Pub. L. 111-48, 24 Stat. 119 (2010); Standards Related to Essential Health Benefits,
Actuarial Value, and Accreditation, 77 Fed. Reg. 70,643, 70,647 (Nov. 26, 2012) (“[T]he Affordable
Care Act explicitly permits a state to require QHPs to offer benefits in addition to EHB, but requires
the state to make payments, either to the individual enrollee or to the issuer on behalf of the enrollee,
to defray the cost of these additional benefits. We propose that state-required benefits enacted on or
before December 31, 2011 (even if not effective until a later date) may be considered EHB, which
would obviate the requirement for the state to pay for these state-required benefits.”). The final rule,
issued on February 25, 2013 maintains these provisions and subjects to the defrayment requirement
for at least the 2014 and 2015 plan years. Id.; Final Rule, 78 Fed. Reg. 12,834, 12,837-8 (February
25, 2013).
74

Id. (“In this proposed rule, we interpret state-required benefits to be specific to the care, treatment,
and services that a state requires issuers to offer to its enrollees. Therefore, state rules related to
provider types, cost-sharing, or reimbursement methods would not fall under our interpretation of
state-required benefits. Even though plans must comply with those state requirements, there would
be no federal obligation for states to defray the costs associated with those requirements.”).
75

See id.

76

See e.g., Assemb. B. 310, 2011–12 Leg., Reg. Sess. (Cal. 2012) (containing provisions that
would make the requirements of the bill inoperative if the Director of the DMHC or the Insurance
Commissioner determines that the requirements would result in the “assumption by the state of
additional costs pursuant to [the requirements of the ACA]”).
77

See ACA, Pub. L. No. 111-48, 124 Stat. 119 (2010); Standards Related to Essential Health
Benefits, supra note 69, at 70,647.
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legislation that seeks to limit the ability of insurers to take advantage of tiering
options.78 While few states have been able to pass such legislation, several active
legislative initiatives remain in place today.79 States have used various mechanisms to
protect individual or household finances against cost-sharing mechanisms, the strongest
of which is the complete ban of specialty tiers. Even more common are out-of-pocket
maximums, which typically take the form of annual limits on the out-of-pocket (OOP)
cost-sharing required by individuals or families.80
As recognition of the serious problem that specialty drug cost-sharing tiers pose for
many of those who depend on those medications, eight states81 have sought a complete
ban on any plan design that contains over a three-tiered pharmacy benefit, effectively
forbidding specialty tiers. Currently, New York is the only state to have legislation that
places a complete ban on specialty tiers.82 An additional nine states83 have sought to
impose caps on the OOP expenditures allowed for pharmaceuticals in health insurance
plans or to link pharmaceutical OOP payments to the overall plan deductible. These laws
have been popular proposals from state legislatures, given that they still allow increased
member cost-sharing for high-cost pharmaceuticals, in accord with insurance company
interests, while protecting beneficiaries from exceedingly high drug costs.84 The second
largest number of states have approved, or are currently considering legislation that
calls for state insurance departments to undertake studies to obtain more information
on the prevalence and effect of specialty tiers, seeking to use the findings to craft
further limiting legislation.85 Often accompanying these studies is a moratorium on the

78

Standards Related to Essential Health Benefits, supra note 69, at 70,653 (proposing that a plan
may exceed the annual deductible limit if it cannot reasonably reach a metal tier).
79

The seven states which have passed laws related to specialty tiering include Alaska, New York,
Delaware, Vermont, Florida, Maine, and Louisiana. Author research.

80

Of the ten states with active bills, six states (Delaware, Nebraska, Pennsylvania, California,
Rhode Island, and Massachusetts) have bills that only lower the cost-sharing limits. Author
calculation. See infra notes 100-106, 119.
81

New York, Delaware, and Vermont have passed and signed into law bans on specialty tiers
for at least certain indications. Only New York has a complete and unlimited ban on specialty
tiers. Legislative efforts to enact bans are ongoing in Kansas, Pennsylvania, California, and
Massachusetts. Mississippi’s legislature considered a complete ban with the same wording as New
York in 2012, but it died in committee. Author research.
82

See Pollack, supra note 43.

83

The states and their provisions are as follows: Delaware, bill, total drug OOP limitation to $100
per month; Maine, law, $3,500 per year OOP maximum; Vermont, law, deductible limitation to
$2,000 per person per year, $4,000 per family per year; Nebraska, bill, specialty tier cannot exceed
500% of OOP cost of lowest tier; Pennsylvania, bill, deductible limitation of $1,000 per person,
$2,000 per family; California, bill, total drug OOP cannot exceed $150 per month and another
bill matching federal deductible limits $2,000 per person, $4,000 per family, California, vetoed by
gov, oral cancer cost-sharing equal to all other cancer drug delivery methods; Rhode Island, bill,
specialty tier cannot exceed 500% of OOP cost of lowest tier and deductible limitation of $1,000 per
person, $2,000 per family; Massachusetts, bill, specialty tier cannot exceed 500% of OOP cost of
lowest tier; Louisiana, law, oral cancer cost-sharing equal to all other cancer drug delivery methods.
Author research. See infra notes 101-113, 119.

84

See e.g., Pollack, supra note 43.

85

See e.g., S.B. 137, 146th Gen. Assemb., Reg. Sess. (Del. 2011).
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approvals of plans with a four-tiered structure until the results of the study have been
analyzed.86
The insurance savings clause of § 514(b)(2)(A) of ERISA grants states the ability to
make such blanket restrictions and limitations on insurance plans.87 Section 514 of
ERISA states that “[e]xcept as provided in subparagraph (B) [the “Deemer Clause”],
nothing in this subchapter will be construed to exempt or relieve any person from any
law of any State which regulates insurance . . . .”88 Effectively, this provision grants state
insurance departments the freedom to regulate plans that operate and/or are offered in
that state as long as the plans are insured plans.89 Accordingly, the savings clause creates
an exception to the general rule that ERISA preempts state laws that relate to employee
benefit plans.90 The purpose of this allowance is to permit states to retain powers over
an area of regulation and an industry which they commonly have had purview.91 The
allowance of additive state regulations of health insurance plans is advantageous for
beneficiaries in those states which have sought to add increased beneficiary protections.
Such regulations, however, can create a patchwork of state regulation that can and do
place a burden on compliance measures for insurance companies that must account
for this multiplicity of laws given that they operate in multiple states.92 The avoidance
of such a situation was a prime consideration in the enactment of ERISA.93 Given
the popularity of specialty pharmaceuticals by pharmaceutical companies and the
86

Id.

87

See ERISA, Pub. L. 93–406, 29 U.S.C. § 514 (b)(2)(A) (providing the construction and
application of various exemptions found within the subchapter of the statute); Metro. Life Ins.
Co. v. Massachusetts, 471 U.S. 722, 733–47 (1985) (considering a Massachusetts mental health
benefit mandate for group health policies; holding that while the mandate “relate[d] to” employee
benefit plans, the law regulated the terms of an insurance contract; and ultimately exempting the
law from pre-emption under the savings clause). In this defining case regarding ERISA’s “savings
clause,” the Court, in coming to its conclusion, applied a three-prong test to determine whether an
activity or practice constitutes the “business of insurance.” Id. at 743 (requiring that the activity
in question must spread risk, the relationship between insured and insurer must be an integral part
of the activity, and it must be limited to entities in the traditional insurance industry (citing Union
Labor Life Ins. Co. v. Pirineo, 458 U.S. 119, 127–30 (1982))). Under this test, the Court concluded
that the Massachusetts mandate and mandated benefits, in general, met all three criteria, and thus
ruled that mandated benefit laws are exempt from pre-emption. Id. at 743, 759; see William Pierron
& Paul Fronstin, ERISA Pre-emption: Implications for Health Reform and Coverage, Emp. Benefit
Research Inst. 1, 8 (Feb. 2008), http://www.ebri.org/pdf/briefspdf/EBRI_IB_02a-20082.pdf.
(distinguishing between plans that are insured and “uninsured,” or self-insured, because the Deemer
Clause would immunize an uninsured plan from state-mandated benefit laws).
88

See ERISA, Pub. L. 93–406, § 514.

89

Id.; see also William Pierron & Paul Fronstin, supra note 87.

90

Contra American Medical Security v. Bartlett, 111 F.3d 358 (4th Cir. 1997); see infra note 119
(explaining the 4th Circuit’s decision).
91

See McCarran-Ferguson Act, 15 U.S.C. §§ 1011-1015 (1976).

92

Such was the purpose of ERISA § 514. See Fort Halifax Packing Co. v. Coyne, 482 U.S. 1, 11
(1987) (finding Congress’s concern with a “patchwork scheme of regulation [that] would introduce
considerable inefficiencies in benefit programs . . . ”).
93

See e.g., Siskind v. Sperry Ret. Program, 47 F.3d 498, 503, 505 (2d Cir. 1995) (observing that the
purpose of ERISA is to provide regulatory consistency and minimize financial and administrative
burdens on employers), abrogated by Janese v. Fay, 692 F.3d 221 (2d Cir. 2012).
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effectiveness of such drugs, however, state actions may be a critical element of reducing
the consumer burdens of healthcare, given that federal legislation that could apply such
restrictions to all states, that goes beyond the limitations imposed by the ACA, seems
not to be feasible.94
A. State Prohibitions of Four-Tiered Plans
It took New York lawmakers over a year and a half, but in 2010, the passage of Senate
Bill 5000B95 marked the first of many state efforts to restrict or limit specialty tier
cost-sharing.96 The New York legislation was a heavily supported bill in that it never
received less than a two-to-one yes-to-no vote margin in any of its committee reviews,
and it eventually passed the New York Senate by a vote of fifty-five to one, with Senator
Thomas O’Mara being the lone nay vote.97 The wave of nationwide support for a similar
ban in other states, however, has not had the success for which many patient advocates
had originally hoped.98 Currently, New York is the only state to have a law that across the
board eliminates specialty tiers without constraints or time limitations.99 Following in the
way of New York legislature by placing complete restrictions on the use of tier four and
higher cost-sharing by insured health plans when offered in that state under the control
of that state’s insurance department are Vermont,100 whose term limited ban expired
on July 1, 2013, and, to a lesser extent, Delaware,101 which only bans four and higher
tiered plans as they apply to oral cancer drugs. Both states’ plans, however, are limited

94

See e.g., Patients’ Access to Treatments Act of 2013, H.R. 460, 113th Cong. (Feb. 4, 2013)
(GovTrack has the bill as having an eleven percent chance of moving past the House Energy and
Commerce Committee and only a three percent chance of passage).
95

Tier IV Prescription Drugs, 2010 Sess. Law News of N.Y. Ch. 536 (S. 5000-B) (McKinney);
(providing that no health care plan or insurance policy that provides prescription drug coverage
and for which cost-sharing, deductibles, or co-insurance obligations are determined by category
of prescription drugs shall impose cost-sharing, deductibles, or co-insurance obligations for
any prescription drug exceeding the dollar amount of cost-sharing deductibles or co-insurance
obligations for any other prescription drug provided under such coverage for non-preferred brand
drugs or their equivalents).

96

See infra part III(B).

97

See S. 5000-2009, Reg. Sess. (N.Y. 2009) (pertaining to the elimination of cost-sharing,
deductibles and co-payments for certain prescription drugs).
98

See National Patient Advocate Foundation, supra note 22.

99

Pollack, supra note 43.

100

See S.B. 104, 2011 Leg., Reg. Sess. (Vt. 2011) (“Prior to July 1, 2012, no health insurer or
pharmacy benefit manager shall utilize a cost-sharing structure for prescription drugs that imposes
on a consumer for any drug a greater co-payment, deductible, coinsurance, or other cost-sharing
requirement than that which applies for a nonpreferred brand-name drug.”).
101

See The Delaware Cancer Treatment Access Act, H.B. 265, 146th Gen. Assemb. Reg. Sess. (Del.
2011) (providing that individual and group health plans in Delaware that provide major medical
and prescription drug coverage will be barred from charging cancer patients higher copayments,
coinsurance, or deductibles for oral chemotherapy drugs, which are in the specialty tier, than for
intravenous therapies, which are covered under medical benefit which does not have specialty tiers).
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in either scope or longevity. Several other states, including Kansas,102 Massachusetts,103
California,104 Pennsylvania,105 and Mississippi,106 have pending legislation that seek
to place complete restrictions on four or higher tier cost-sharing in plans. Currently,
Mississippi is the only state where its legislature passed a complete, unrestricted ban but
the Governor vetoed the bill.107
Surprisingly, the New York State law was passed even though there was never an issue
in New York with specialty tiers.108 The New York State Insurance Department never
authorized a commercial health insurance plan that contained specialty tiers before
the introduction of this legislation, although there had never been an official law in
New York regarding this practice until New York Senate Bill 5000’s introduction.109
A memorandum in opposition to the legislation, from the law firm of Hinman Straub
P.C. written on behalf of Blue Cross and Blue Shield Plans of New York, stated that
Senate Bill 5000-B was redundant and unnecessary because no private health insurance
plan that contained specialty tiers previously had been approved by the State Insurance
Commissioner.110 Because the New York legislation did not attempt to prevent a practice
that was already in place, advocates neither expected nor confronted a forceful opposition

102

See H.B. 2136, 84th Gen. Assemb., Reg. Sess. (Kan. 2011) (“It shall be an unlawful
discriminatory practice . . . [f]or any employer, labor organization, insurer, health maintenance
organization or other entity to limit health care coverage such that cost-sharing, deductibles or
coinsurance obligations for any prescription medication exceeds the dollar amount of cost-sharing,
deductibles or coinsurance obligations for any category of non-preferred brand medication or its
equivalent, or brand medication if there is no non-preferred brand medication category.”).
103

See S.B. 455, 187th Gen. Assemb., Reg. Sess. (Mass. 2012) (providing that an insurer shall not
create specialty tiers that require payment of a percentage cost of prescription drugs).
104

See Assemb. B. 310, 2011–12 Leg., Reg. Sess. (Cal. 2012) (“A health insurance policy issued,
amended, or renewed on or after January 1, 2012, that covers outpatient prescription drugs shall not
require coinsurance as a basis for cost-sharing with the insured for outpatient prescription drugs
shall not require coinsurance as a basis for cost-sharing with the insured for outpatient prescription
drug benefits.”).
105

See H.B. 1609, 2011 Leg., Reg. Sess. (Pa. 2012) (“An insurer shall not create specialty tiers that
require payment of a percentage cost of prescription drugs.”).
106

See H.B. 1319, 2012 Leg., Reg. Sess. (Miss. 2012) (“A health care service plan contract issued,
amended, or renewed on or after January 1, 2013, that covers prescription medicine shall not create
specialty tiers that require payment of a percentage cost of prescription drugs.”). This bill has been
reintroduced but previously died in committee on March 6, 2012. Id.
107

See id. (pertaining to all health care service plans issued, amended, or renewed on or after
January 1, 2013).
108 See Haley Gillet et al., Regulating the Specialty Tier in Georgia, Ga. Tech. Pub. Pol’y Task
Force 2012, 24 (2012), http://www.advocatesforresponsiblecare.org/uploads/GRC_Specialty_Tier_
GA_Tech_Final_Report_Regulating_the_Specialty_Tier.pdf.
109

See id. (observing that an important element was that this bill did not incur any costs on
New York State; rather, no additional state oversight was necessary to regulate and monitor the
elimination of drug formularies containing a specialty tier because they had never been approved by
the Insurance Department).
110

Memorandum from Hinman Straub P.C. Legislative Counsel for the Blue Cross and Blue Shield
Plans (Apr. 15, 2010), http://www.nysblues.org/pdf/A8278AS5000A.pdf.
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from the insurance industry.111 The insurance industry was only mildly opposed and did
not employ any massive campaign in resistance to the New York legislation.112
According to New York Senate Bill 5000, cost-sharing policies in general create negative
health outcomes because they decrease the utilization of drugs, which may lead to
increased hospitalizations to address the consequences of foregoing treatment.113 With
the degree of cost-sharing in specialty tiers, the legislature found these detrimental effects
to be uncontainable.114 In its legislative findings, Senate Bill 5000-B indicates that “[t]he
cost-sharing, deductibles and co-insurance obligations for certain drugs are becoming
cost prohibitive for persons trying to overcome serious and often life-threatening
diseases and conditions such as cancer, multiple sclerosis, rheumatoid arthritis, hepatitis
C, hemophilia and psoriasis.”115 As an attempt to avoid such limitations on patient care,
§ 3216 of New York State’s insurance law was amended by adding paragraph 27, which
provides that “[n]o policy delivered or issued for delivery in this state which provides
coverage for prescription drugs and for which cost-sharing, deductibles or coinsurance
obligations are determined by category of prescription drugs shall impose cost-sharing,
deductibles or co-insurance obligations for any prescription drug that exceeds the dollar
amount of cost-sharing, deductibles or co-insurance obligations for non-preferred
brand drugs or its equivalent (or brand drugs if there is no non-preferred brand drug
category).”116 The effect of this amendment is to limit the maximum cost-sharing to
the level required for non-preferred brand name drugs, typically referred to as tier three
pharmaceuticals.117
B. Cost-Sharing Limits Falling Short of Prohibitions
While many states have entertained bills that seek to limit specialty drug cost-sharing,
many others have resisted such proposals in order to avoid drawing the ire of insurers in
the state, or, for fear that such measures would increase premiums for all beneficiaries—
regardless of whether they use drugs covered in the specialty tier.118 Thirteen states
either have passed laws or currently have proposed legislation that would place caps on
111

Gillet et al., supra note 108, at 26.

112

See id. (reasoning that the legislation would maintain the status quo).

113

See e.g., Kris McFalls, supra note 35 (comparing how various states have passed legislation to
ban specialty tiers but eventually opining that such legislation will no apply to self-funded plans
under ERISA).
114

See Tier IV Prescription Drugs, 2010 Sess. Law News of N.Y. Ch. 536 (S.B. 5000-B)
(McKinney) (explaining that such drugs are usually produced in smaller quantities than are other
drugs and are unavailable as less expensive generic drugs).
115

See id. (asserting that it is in the public interest to provide assistance to patients to afford
necessary prescription drugs and that the “extraordinary disparity in cost-sharing, deductible and
co-insurance burdens imposed on patients whose life and health depend on these drugs constitutes
serious and unjustified discrimination based on their disease or disability”).
116

See id. (intending to provide patients a more affordable access to essential prescription drugs).

117

See Tier IV Prescription Drugs, 2010 Sess. Law News of N.Y. Ch. 536 (S. 5000-B) (McKinney)
(“No policy . . . shall impose cost-sharing, deductibles or co-insurance obligations for any prescription
drug that exceeds the dollar amount of cost-sharing, deductibles or co-insurance obligations for nonpreferred brand drugs or its equivalent.”).
118

See supra notes 100-106 (listing the enacted legislation and active bills).
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specialty drug spending,119 create moratoriums on the creation of new tier four benefit
structures,120 or directed state insurance departments to explore specialty cost-sharing
limitations.121 The most common of these measures is a limitation on the extent of costsharing such that the difference between the lowest and the higher cost-sharing amounts
among all tiers cannot exceed 500%.122 This effectively eliminates coinsurance and
instead replaces it with a limited copayment feature. Seeing as drugs in the first tier can
have OOP amounts as low as five dollars, the ability of insurance companies to attain
119

Several states have enacted laws that limit cost-sharing: Maine, Louisiana, and Vermont. See
Me. Rev. Stat. tit. 24-A, § 4317-A (2012) (“[F]or all benefits provided under a health plan, the
carrier shall establish a separate out-of-pocket limit not to exceed $3,500 per year for prescription
drugs subject to coinsurance provided under a health plan to the extent not inconsistent with the
federal Affordable Care Act.”); H.B. 693 2012 Leg., Reg. Sess. (La. 2012) (requiring parity for
orally administered anti-cancer medications with intravenously administered or injected anticancer medications); H.B. 559, Reg. Sess. (Vt. 2012) (establishing an annual out-of-pocket limit
for prescription drugs at two thousand dollars per individual and four thousand dollars per family);
Del. Gen. Stat. Ch. 33 §3364 (S.B 35, 147th General Assembly) (De. 2013) (indicating that a health
plan that provides coverage for prescription drugs shall not have cost-sharing of more than $100 per
month for up to a 30-day supply of any single drug, and cannot charge more than $200 per enrollee
per month in the aggregate for covered pharmaceuticals).
Various bills that limit cost-sharing exist in other states, too. See e.g., S.B. 455, Reg. Sess.
(Mass. 2012) (providing no cost-sharing more than five-hundred percent of the least expensive drug
category); Legis. B. 322, 102d Leg. 1st Reg. Sess. (Neb. 2012); S.B. 252, 146th Gen. Assemb., 2d
Reg. Sess. (Del. 2011) (stating that any required copayment or coinsurance that applies to covered
drugs cannot exceed $100 per month for up to a thirty-day supply of any single drug, whereby such
required copayment or coinsurance does not exceed, in the aggregate for all covered drugs, $200 per
month per enrollee). “An insurer shall not create specialty tiers that require payment of a percentage
cost of prescription drugs” that cost more than 500% of the lowest price prescription drug. H.B.
1609, 2012 Leg. Reg. Sess. (Pa. 2012) (no plan can create a specialty tier and maximum copay
cannot exceed lowest by 500%). See Assemb. B. 310 (stating that “health insurance policies . . . shall
not require an insured to pay a copayment for outpatient prescription drugs in excess of one hundred
fifty dollars ($150) for a one-month supply of a prescription, or its equivalent for a prescription for a
longer period, as adjusted for inflation”).
A more recently introduced bill, which created a limit on out-of-pocket expenses at the level set
by the federal OOP limit, died in the appropriations committee on August 16, 2012. See Assemb.
B. 1800, 2012 Leg. Gen. Sess. (Cal. 2012); see also H.B. 7573, 2012 Leg. Reg. Sess. (R.I. 2012)
(providing that no tiers shall be created where the maximum cost-sharing exceeds the lowest in the
plan by 500% or more).
120

Currently, both Florida and Delaware have such laws. See H.B. 1003, 115th Leg. 2d Reg. Sess.
(Fla. 2013) (creating specialty tier prescription drug moratorium for a year until July 1, 2014, and
requiring a report to the Governor and Legislature as to cost-sharing effects.); S.B. 137, 146th Gen.
Assemb., Reg. Sess. (Del. 2011) (creating a moratorium on health insurance providers that charge
higher cost-sharing for different classification of prescription drugs until the Legislature enacts
legislation to limit such higher cost-sharing is not needed, and moreover requiring that by March
15, 2012, the Delaware Healthcare Commission submit to the General Assembly a report that
summarizes the impact of specialty cost-sharing).
121

States who have enacted such requirements include: Florida (See supra, note 119), Delaware
(See supra, note 119), and there is a bill in Illinois to extend the period, by a year, to deliver their
previously required report which would be due under the bill on November 30, 2013. 2011 IL H.R.
1310 (NS), 2011 Illinois House Resolution No. 1361, Illinois Ninety-Seventh General Assembly
(Jan. 6, 2013).
122

See supra, note 119.
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any real assistance in covering the excessive costs of specialty drugs is severely limited.
Many other states have targeted or enacted numerical limits as a way to ensure that
cost-sharing in the specialty tier cannot rise above a certain set amount.123 This strategy
is much more feasible and yet remains highly effective in that it would allow a costsharing amount to be imposed relative to the cost of specialty pharmaceuticals, allowing
the beneficiary to share in some, albeit small, amount of the cost of the specialty drugs
they use. This structure would not cause as much upward pressure on the cost-sharing
for other drug categories, while still limiting the total costs to those beneficiaries who
depend on such specialty drugs.
Pharmaceutical companies have been active in lobbying for state legislatures to
introduce legislation that limits cost-sharing.124 For instance, legislators in Maine have
reported in-depth discussions with Pfizer, and some pharmaceutical companies have
even supplied draft bills that may be introduced by state legislatures.125 Pharmaceutical
companies seek such limits as this creates a wider market for their drugs and helps
to insure the patient will actually fill their prescriptions for specialty pharmaceuticals
and not be deterred from doing so based on high costs.126 Noncompliance to a drug
regimen is one of the more damaging externalities of high cost-sharing, not only
for pharmaceutical companies but also for health care more generally. However, the
country’s largest health insurance companies have been more active and have effectively
ended reform movements in some states.127 The incentives for insurance companies to
oppose such reforms are obvious as the loss of specialty tier cost-sharing greatly affects
not only their bottom line but also the risk pool of their health insurance plans.128

III. Why Section 514 of ERISA Has Limiting
Effects on State Efforts
State legislative attempts to limit specialty pharmaceutical cost-sharing are severely
limited by ERISA’s express preemption of state laws that “relate to” employee benefit
plans and which are not saved under the insurance savings clause.129 Some experts
and advocates have argued that the preemption provision in § 514 of ERISA is overly
restrictive in that it “prevents state and local governments from regulating employmentbased health plans,” limiting the potential for comprehensive health insurance reform to
start at the state or local level where such legislation is often more easily legislated.130
For instance, in accordance with ERISA, state specialty tier laws cannot impact selffunded employee health plans which are under the sole purview of ERISA and federal
123

Id.
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Pollack, supra note 43.

125

Id.
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See National Patient Advocate Foundation, supra note 22.

127

See Pollack, supra note 43.

128

See e.g., 2012 Drug Trend Report, supra note 17 (showing the emergence of specialty drugs as
the most lucrative of all pharmaceuticals).
129

See ERISA, 29 U.S.C. §§ 514(b)(2)(A), (B).

130

William Pierron & Paul Fronstin, ERISA Pre-emption: Implications for Health Reform and
Coverage, 8 EBRI Issue Brief no. 314, 38 (Feb. 2008), http://www.ebri.org/pdf/briefspdf/EBRI_
IB_02a-20082.pdf.
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regulations.131 This is arguably detrimental considering that over half of all employees
with health insurance coverage are enrolled in self-funded employer sponsored plans.132
Under the “insurance savings clause” of ERISA, all state laws that govern the business
of insurance, such as limitations on cost-sharing, are exempt from ERISA preemption as
they apply to insured plans—as established in § 514 of ERISA.133 All insured employee
benefit plans are deemed to be included under the umbrella of the insurance savings
clause, and as such, state insurance law mandates apply to these plans—as long as they
are additive to ERISA mandates.134 Conversely, ERISA’s “Deemer Clause” declares that
self-funded plans135 are not deemed to be in the business of insurance; and are therefore
exclusively under the purview of ERISA, and federal mandates that amend ERISA,
such as the ACA.136 As such, these plans do not have to comply with state mandates that
require more than federal minimum coverage and plan design requirements.137
The insured/self-insured split is the result of congressional intent that ERISA provide
a legal framework for the uniform provision of benefits by employers doing business
anywhere in the country.138 This uniformity allows multistate companies that self-insure
to offer consistent benefit packages wherever they happen to be located. The result of
which is ease of administration and lower expenses to ensure plan compliance.139 For
self-insured plans, freedom from state benefit mandates also allows plan sponsors to
design benefit packages that meet the needs and desires of their employees, as well as to
131

See supra notes 64–67.

132

Pierron & Fronstin, supra note 130; Carolyn Johnson, Bill Aims to Stop Specialty Tier
Prescription Drug Costs, ABC News San Francisco, Feb. 9, 2011, http://abclocal.go.com/kgo/
story?section=news/health&id=7950299. It is important to note that an increasing number of
such self-funded plans do feature stop-loss protections that seek to limit the potential losses of the
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effectively promote wellness and control health costs.140 Such unique needs, as well as
the risk that these employers have assumed in their self-insured plans, are some of the
primary reasons why they are allowed to largely escape state insurance regulations.141
Due to ERISA, state legislation limiting specialty tiering, even if passed in all fifty states,
will not apply to self-funded plans.142 Federal legislation—such as the reform measures
enacted in the ACA—is needed to address ERISA-governed plans, particularly to attain
a universal application of limits. Given the number of beneficiaries in self-insured
employer plans, the federal reform approach would have a much larger influence on the
market.143 Such a federal measure was introduced in the U.S. House of Representatives
on February 4, 2013 by Representative David McKinley. The Patients’ Access to
Treatments Act of 2013,144 “amend[s] title XXVII of the Public Health Service Act
to limit co-payment, coinsurance, or other cost-sharing requirements applicable to
prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of
such requirements applicable to prescription drugs in a non-preferred brand drug tier,
and for other purposes.”145 This bill is similar to the law enacted in New York in that
it effectively bans the usage of specialty tiers by setting the maximum pharmaceutical
cost-sharing, which is equal to the rate for non-preferred brand drugs—traditionally the
third tier.146 With eighty-five co-sponsors across both parties (sixty-seven Democrats
and eighteen Republicans) there appears to be support for such a bill; however, it
will require much more support to transverse the current state of federal politics.147
While such a measure is assuredly gaining the ire of health insurance advocates, such
a measure would prove beneficial to those states that have been wrestling with this
issue for a number of years.148 This bill could essentially solve both the state legislative
backlog and the insured/self-insured dichotomy in one legislative act. Since this is a
reintroduced bill, however, it is hard to overlook its past failures, especially with all of
the recent burdens placed on insurers by the ACA.149
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IV. Will the Affordable Care Act Make State Action on
Specialty Tiers less Palatable?
While the ACA creates a cost-sharing limit that will apply to all health benefit plans,
further state out-of-pocket (OOP) restrictions are necessary because the ACA limits
remain prohibitively high for some of the beneficiaries that are most in need.150 However,
some states fear that any increased benefits may trigger an ACA requirement that would
require states to defray the extra costs of offering such increased benefits.151 The costsharing limits set forth in the ACA are pegged to the OOP limits for high-deductible
health plans (HDHPs).152 The cost-sharing limits for HDHPs in 2014 are $6,350 for an
individual or $12,700 for “family” coverage.153 This amount is corrected for inflation
and generally increases yearly—the 2013 HDHP limit was $6,250 for an individual and
$12,500 for “family” coverage.154 While the restrictions this places on cost-sharing will
surely limit the high coinsurance rates that some beneficiaries are required to pay, given
their health conditions and the prices for the pharmaceuticals on which they depend, for
many Americans these capped amounts can still be extremely burdensome or even cost
prohibitive for those on fixed incomes who may not be able to access federal or state
health benefits.155 And the affordability does not appear to be improving for the 2015
benefit year, as Centers for Medicare and Medicaid Services (CMS) on November 26,
2013 issued its proposed 2015 Notice of Benefit and Payment Parameters rule, in which
it calls for the OOP limits to be raised by four times the amount the Internal Revenue
Service (IRS) raised the HDHP rates for 2014; CMS proposed that the 2015 maximum
annual limitation on cost-sharing be $6,750 for self-only coverage and $13,500 for
“family” coverage.156 As such, there may be an even greater need now for states to act
to reduce the burden on beneficiaries who depend on specially drugs.
As state legislators consider laws that would prohibit or limit cost-sharing, the ACA
has created a wrinkle that may cause budget conscious state governments to think twice
about enacting such legislation. It is still unknown if legislation that places limits on
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cost-sharing for prescription drugs would create a new mandate subject to the ACA
requirement that for coverage provided through the Exchange, the State is required to
pay the full cost of any new mandate exceeding the covered services required in that
state’s Essential Health Benefits (EHB) Package.157 Section 1311(d)(3)(B) of the ACA,
which is more acutely defined in a November 2012 Department of Health and Human
Services (HHS) proposed rule (final rule, issued on February 28, 2013, maintains such
provisions but does not speak as directly to its application), allows states to create
mandated benefits for exchange plans, above and beyond those required elsewhere in
the ACA (EHBs), as long as the state defrays the additional costs.158 Since coverage
for prescription drugs is included as one of the ten required EHBs, state laws related
to additional pharmaceutical benefits must comply with this requirement.159 Within the
EHB design template, there is a clearly demarcated area for the inclusion of specialty
drug tiers.160 In addition, the actuarial value calculator, which is used to calculate the
coverage level for the plan, known as “metal tiers,”161 includes the option of adding a
specialty drug tier cost-sharing amount that will be used to calculate the average plan
cost to the beneficiary.162
The November 2012 rule, however, explicitly states that cost-sharing legislation is not a
mandate that will trigger the state to defray costs, allowing states to pass such laws without

157 ACA, Pub. L. No. 111-48, § 1311 (d)(3)(B), 124 Stat. 119 (2010); see also 77 Fed. Reg. 70,643,
70,647 (Nov. 26, 2012). The ACA left states with the requirement that they establish an essential
health benefit plan for that state—within certain parameters. Such a plan mirrored a specific existing
plan in the state augmented, where required, such that the plan features would be compliant with
the ACA. Such existing plans already contained current state mandates that survived ERISA §
514. However, if the state where to add required benefits or plan features above and beyond the
ACA requirements after the adoption of an EHB benchmark plan, the state would be required to
reimburse the insurance company for the provision of such benefits or plan features where they
augmented the EHB or ACA requirements. Id.
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suggested in the rule by calculating the additional costs incurred by the plan and spreading that cost
across all plan beneficiaries. The state will then pay to the plan on behalf of each beneficiary or to
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the fear of triggering the defrayment requirement of § 1311(d)(3)(B) of the ACA.163
According to the CMS proposed rule, CMS will, “interpret state-required benefits to
be specific to the care, treatment, and services that a state requires issuers to offer to its
enrollees. Therefore, state rules related to provider types, cost-sharing, or reimbursement
methods would not fall under our interpretation of state-required benefits. Even though
plans must comply with those state requirements, there would be no federal obligation
for states to defray the costs associated with those requirements.”164 Legislative studies
conducted in California165 and Maryland166 suggest that a bill that restricts forms of
cost-sharing does not create a mandated covered service; rather, it places restrictions on
cost-sharing designs that can be used to craft the levels of cost-sharing within the EHB
benchmark plan.167 In an attempt to reduce the risk of a conflicting interpretation, some
states considering going forward with specialty tier limiting legislation have included
escape provisions in their legislation.168 For example, a California specialty tier limiting
bill includes language that would make the bill inoperative if it were determined that the
requirements would result in the assumption by the state of additional costs pursuant
to § 1311(d)(3)(B) of the ACA.169 The use of such language in other states bills should
allow them to pursue specialty tier cost-sharing legislation without the risk that such
provisions would activate the ACA requirement that would require states to defray costs.

Conclusion
Specialty drugs represent a growing concern for both health insurance issuers and
beneficiaries given their exceedingly high cost. They are projected to represent almost
half of all drug spending by 2017.170 Payers have sought to reduce specialty drug spending
by sharing more of the cost of these drugs with the beneficiaries who depend on them
163 ACA, Pub. L. No. 111-48, 124 Stat. 119 (2010); Standards Related to Essential Health Benefits,
Actuarial Value, and Accreditation, 77 Fed. Reg. 70,643, 70,647 (Nov. 26, 2012) (in accord with the
final rule which appears at 78 Fed. Reg. 12834, 12837-8, http://www.gpo.gov/fdsys/pkg/FR-201302-25/pdf/2013-04084.pdf).
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166 2011 Session Position Paper regarding H.B. 251, Maryland Health Care Commission (2011),
http://dls.state.md.us/data/tabs/wha/Issue-Papers—-2012-Legislative-Session-for-web.pdf.
167 See supra note 165. California argues that AB 310 does not require coverage of additional
benefits as it specifically states, that “[n]othing in this section shall be construed to require a [health
care service plan/health insurance policy] to provide coverage not otherwise required by law for any
prescription drug.” Id. The California report also lists several factors that would be considered by
the Department of Insurance in deciding whether there was a mandated benefit that would require
the state to defray the extra costs to the plans. Id. at 23.
168 For instance, AB 310 contains provisions that would make the requirements of the bill
inoperative if the Director of the DMHC or the Insurance Commissioner determines that the
requirements would result in the “assumption by the state of additional costs pursuant to Section
1311(d)(3)(B) of the federal Patient Protection and Affordable Care Act (Public Law 111-148), as
amended by Section 10104(e) of Title X of that act, relative to benefits required by the state to be
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through the creation of specialty drug tiers.171 This has forced some patients to choose
between forgoing other needs to pay for their medications or not take their medications
at all. While several states have sought to outlaw the use of specialty drug tiers or limit
pharmaceutical OOP cost-sharing, only New York has been successful in passing an
unlimited prohibition on specialty tiers.172 There are, however, currently legislative
efforts in a quarter of states that seek to either limit or eliminate cost-sharing requirements
for beneficiaries who depend on specialty pharmaceuticals for treatment.173 While some
state legislatures have been concerned that the ACA cost defrayment requirement that
applies to new state required benefits that are above and beyond the required benefits
in that state’s EHB benchmark plan, the November 2012 HHS Essential Health Benefit
proposed rule makes it explicit that state laws concerning cost-sharing limitations do not
implicate the requirement to defray costs—they merely effect benefit designs, not the
number of EHBs.174 For those states that remained skeptical of this CMS interpretation
of the ACA, there is the option of constructing the legislation in such a way that the
specialty pharmaceutical cost-sharing limitations would be inoperative should the state
be required to defray the costs of such additional benefit features—as has been done
in both California and Maryland.175 Whether such protections are written in, given the
CMS interpretation and its appearance in the February EHB final rule, CMS has provided
states will an opportunity to limit the burdensome OOP costs that are associated with
specialty drugs. Doing so could allow beneficiaries to not have to choose between their
medications and basic necessities.176 While the ACA caps on OOP expenditures go far
in reducing the most egregious cases of specialty pharmaceuticals spending, it does not
go far enough, and in fact such limits will continue to rise yearly (the limits are slated to
rise by $1,000 for families in 2015), providing less and less protection; states must act
to further remove or limit the constraints that specialty tier OOP requirements place on
beneficiaries who many times have no other treatment options.177
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